Site search

Are you interested in learning more about how you can protect and improve your brain health? We would like to invite you to our Brain Health Open Days, where you can find out the latest information about prevention, risk reduction and maintaining a healthy brain throughout your life.

When Frank’s wife Moira moved into residential care, he set off on an extraordinary fundraising walk that took him more than 170 miles along the cliff tops, shorelines and footpaths of the Scottish Highlands. Frank has raised over £35,000 for Alzheimer Scotland. 

Every year on 21 September, World Alzheimer’s Day brings global attention to Alzheimer’s disease and other forms of dementia. It’s a time to raise awareness, fight stigma, and highlight the ongoing need for research and support for people living with dementia and their families and carers.

Following on from our Annual Conference, we will be hosting a special seminar on Monday 23 September highlighting some of the innovative projects from the Alzheimer Scotland Centre for Policy and Practice (ASCPP).  

When Bob, 67, was diagnosed with young onset Alzheimer’s disease in 2018, it came as a huge shock. His daughter Dorota talks about how their Post Diagnostic Support Link Workers provided a supportive lifeline for the whole family.

We are aware that there are currently door to door fundraisers from dementia charities operating throughout Scotland. We want to reassure you that these fundraisers are not from Alzheimer Scotland and we do not use cold calling methods at any time.  

National Records of Scotland has today published a new report on dementia deaths in 2023. Read our response to this report. 

Residents and staff at an Edinburgh care home have joined a fundraising challenge that pays tribute to people with dementia by walking more than three miles around their gardens.

Andrew describes how he teamed up with his twin brother Grant and their dad Ian for the Dundee Kiltwalk to raise vital funds in honour of their grandmother Ruby, who is living with Alzheimer’s disease. 

UK medicines regulator MHRA has approved the new Alzheimer’s drug, lecanemab, for use in the UK. However, an interim decision by NICE has deemed lecanemab not cost-effective for the NHS.